Rodman & Renshaw Reiterates NeoStem Market Outperform, $3 PT

Rodman & Renshaw reiterated its NeoStem NBS Market Outperform and $3 price target in a research report published today. In the report, Rodman & Renshaw states, "According to our projections, NeoStem should have $16 MM in cash and cash equivalents when reporting 2Q11 results, with approximately 95 MM basic shares outstanding and 152 MM fully dilutive shares of outstanding. Together with an $18 MM equity line of credit, the cash position should be sufficient to fund operations through 1Q12." Shares of NeoStem were trading at $1.05 at the time of posting, down 0.94% from Tuesday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorReiterationAnalyst RatingsFinancialsMulti-line InsuranceRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!